Morning Market Brief: Biotech Names Stir as VENU Rockets on FireSuite Sales

October 8, 2025

DENVER, Colo., Oct 08, 2025 (247marketnews.com)- VENU (NYSE:VENU) reported that its Luxe FireSuites have generated over $23 million in demand over the past 60 days alone, $10.7 million in August and $12.3 million in September, marking a record pace in investor interest. This surge reinforces VENU’s “fan-first real estate” model, where ownership of premium suites blends experiential appeal with long-term revenue potential. Institutional backing seems to be aligning, and VENU is actively expanding into new markets like El Paso, Dallas, and Tulsa.

Wall Street coverage has begun to echo the enthusiasm: Cenorium Capital: Strong Buy, $22 target, Think Equity, Buy $18, Northland Securities: Raised from $15 to $17, Buy rating maintained, and Freedom Broker: Buy, $15.30.

VENU’s recent $34 million institutional round completed by ThinkEquity at approximately $12 per share further solidified the company’s base valuation.

Xenetic Biosciences (NASDAQ:XBIO) is gaining momentum after expanding its R&D collaboration with The Scripps Research Institute to validate its systemic DNase platform in new hematologic and solid tumor models. The company is advancing its DNase‑I candidate (XBIO‑015) as an adjunct to CAR‑T therapies, aiming to suppress neutrophil extracellular traps (NETs) that may diminish therapeutic responses. Xenetic also recently reported a net loss of ~$0.7 million in Q2 while cutting costs and continuing translational work ahead of its IND ambitions.

AlphaTON Capital (NASDAQ:ATON) and its oncology subsidiary Cyncado Therapeutics are pushing the boundaries of decentralized science (DeSci) by exploring tokenization of the economic rights to TT-4, their lead mesothelioma drug candidate. Through a non-binding LOI, the companies plan to merge their blockchain expertise, rooted in the TON ecosystem and Telegram’s billion-user base, with life sciences, offering a unique financing framework to accelerate cancer drug development. This initiative positions AlphaTON as the only Nasdaq-listed company combining digital asset infrastructure with a clinical-stage immunotherapy pipeline, leveraging validator services, staking, and tokenization to drive DeSci’s potential.

TT-4, a selective A2B receptor antagonist, has shown compelling preclinical results in mesothelioma models, including over 90% tumor inhibition and strong synergy with anti-PD-1 therapies. With first-patient dosing targeted for Q1 2026, the tokenization model could broaden stakeholder engagement and funding access while maintaining traditional development and licensing paths. AlphaTON’s approach is designed to align global supporters with therapeutic outcomes, enhance transparency, and accelerate innovation, all while preserving regulatory compliance and optionality for future partnerships or acquisitions.

Universe Pharmaceuticals (NASDAQ:UPC) is trying to reenter the radar after it was was recently hit with a Nasdaq staff determination notice over its failure to file its FY2024 20‑F, and followed up with a 40‑for‑1 reverse share split aimed at restoring listing compliance. If Universe can clear those hurdles, either with SEC filings, a capital raise, or an updated clinical/strategic announcement, it may swing back into investor view and trade among the week’s most volatile names.

Acurx Pharmaceuticals (NASDAQ:ACXP) brings a more clinical-development angle into the mix. Though lower profile compared to larger players, Acurx is advancing its pipeline of anti-infectives, especially given rising demand for novel antimicrobial therapies in the face of increasing resistance rates. Any positive data readouts, trial enrollment news, or regulatory designations (e.g. Fast Track or QIDP) could catalyze renewed investor interest—and potentially push ACXP into the biopharma limelight this week.

TransCode Therapeutics (NASDAQ:RNAZ) acquired Polynoma LLC, a privately held biotech firm focused on immuno-oncology, along with a $25 million equity investment from CK Life Sciences, Polynoma’s former parent. The strategic deal significantly strengthens TransCode’s clinical pipeline by adding seviprotimut-L, a Phase 3-ready polyvalent shed antigen vaccine for adjuvant treatment of stage IIB and IIC melanoma. The funding will also support advancement of TransCode’s lead microRNA candidate, TTX-MC138, into a Phase 2 trial targeting metastatic cancers.

As part of the leadership transition, Dr. Philippe Calais has been appointed CEO while remaining Chairman of the Board. Tom Fitzgerald will resume his role as CFO, and Elizabeth Czerepak has joined as an independent board member and Audit Committee Chair. TransCode plans to integrate Polynoma’s clinical and operational teams, creating a unique oncology platform that combines microRNA therapeutics with late-stage immuno-oncology assets. The company sees potential synergies between its technologies in addressing both macro and micrometastatic disease, particularly in hard-to-treat cancers like melanoma.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

For the full 24/7 Market News VENU report and in-depth insights, including analyst reports, visit: Read 24/7 Market News VENU Report/

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

About Venu Holding Corporation

Venu Holding Corporation (NYSE American:VENU) is redefining the live entertainment landscape through a national network of premium amphitheaters powered by its Luxe FireSuites model. With partnerships like AEG and Aramark, and an active development pipeline of over $5 billion (including $1 billion underway), Venu is building the next generation of destination venues, where investors, fans, and artists come together in a hospitality-first experience.

Through its innovative 40/40/20 financing model and integrated hospitality campuses, the company is building a national network of premium amphitheaters and entertainment destinations, targeting 40 venues by 2030. Its flagship Ford Amphitheater was nominated as Pollstar’s Best New Venue of 2024.

24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, XBIO, ATON, UPC, ACXP, RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.